Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Yan Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3843-5240; OpenAlex author ID A5101551629. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 1 paper · 2025: 1 paper

Papers 15

  1. Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis Co-author DOI 10.21203/rs.3.rs-5324510/v2↗
  2. Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells. Co-author DOI 10.36721/pjps.2024.37.2.reg.327-336.1↗
  3. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.1155/2023/3419401↗
  4. Time trend of pancreatic cancer mortality in the Western Pacific Region: age-period-cohort analysis from 1990 to 2019 and forecasting for 2044. Co-author DOI 10.1186/s12885-023-11369-1↗
  5. Comprehensive Analysis Identifies PKP3 Overexpression in Pancreatic Cancer Related to Unfavorable Prognosis. Co-author DOI 10.3390/biomedicines11092472↗
  6. The Global, Regional and National Burden of Pancreatic Cancer Attributable to Smoking, 1990 to 2019: A Systematic Analysis from the Global Burden of Disease St… Co-author DOI 10.3390/ijerph20021552↗
  7. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Reveals That TAM2-Driven Genes Affect Immunotherapeutic Response and Prognosis in Pancreatic … Co-author DOI 10.3390/ijms241612787↗
  8. Immunocyte Infiltration Analysis and Immunohistochemistry Identify EVL as a Potential Prognostic Biomarker for Pancreatic Cancer. Co-author DOI 10.3390/jpm13030433↗
  9. The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. Co-author DOI 10.1016/j.bbcan.2022.188826↗
  10. Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. First author DOI 10.1155/2022/4661929↗
  11. Overexpressed CA12 has prognostic value in pancreatic cancer and promotes tumor cell apoptosis via NF-κB signaling. Co-author DOI 10.1007/s00432-020-03447-9↗
  12. Discovery and Validation of Circulating EVL mRNA as a Prognostic Biomarker in Pancreatic Cancer. Co-author DOI 10.1155/2021/6656337↗
  13. Expression and prognostic analyses of SCAMPs in pancreatic adenocarcinoma. Co-author DOI 10.18632/aging.202377↗
  14. PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling. Co-author DOI 10.1002/jcp.29685↗
  15. High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-κB Pathway in Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2020/8868245↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wence Zhou · 7 shared papers, 2022–2023 · strength 1.53
  2. Wenkai Jiang · 6 shared papers, 2022–2023 · strength 1.34
  3. Huaqing Shi · 4 shared papers, 2022–2025 · strength 0.93
  4. Zhou Chen · 4 shared papers, 2022–2025 · strength 0.93
  5. Zechang Xin · 5 shared papers, 2020–2021 · strength 0.66
  6. Peng Xu · 5 shared papers, 2020–2021 · strength 0.66
  7. Feiyu Mao · 5 shared papers, 2020–2021 · strength 0.66
  8. Jie J. Yao · 5 shared papers, 2020–2021 · strength 0.66
  9. Chunlu Dong · 2 shared papers, 2024–2025 · strength 0.51
  10. Fangfang Han · 2 shared papers, 2024–2025 · strength 0.51
  11. Wence Zhou · 2 shared papers, 2023–2024 · strength 0.48
  12. Xin Li · 2 shared papers, 2023 · strength 0.46
  13. Shi Dong · 2 shared papers, 2023–2024 · strength 0.45
  14. Jianjun Qian · 3 shared papers, 2020–2021 · strength 0.36
  15. Zhennan Li · 3 shared papers, 2020–2021 · strength 0.36
  16. Wence Zhou · 1 shared paper, 2025 · strength 0.27
  17. Duguang Li · 2 shared papers, 2020 · strength 0.23
  18. Wenlong Zhang · 1 shared paper, 2022 · strength 0.22
  19. Xin Li · 1 shared paper, 2023 · strength 0.22
  20. Xiao Li · 1 shared paper, 2023 · strength 0.22
  21. Qingbo Feng · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.